Individual susceptibility to asparaginase therapy has potential to inform its utilisation across the subtypes of leukaemia on a case-by-case basis, perhaps changing the outlook on asparaginase as an increasingly targeted therapy for both ALL and AML. This evidence concerns the gene ASPG and leukemia.